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Abstract
In resource-limited settings, beliefs about disclosing a child’s HIV status and the subsequent impacts of dis-
closure have not been well studied. We sought to describe how parents and guardians of HIV-infected children
view the impact of disclosing a child’s HIV status, particularly for children’s antiretroviral therapy (ART)
adherence. A qualitative study was conducted using involving focus groups and interviews with parents and
guardians of HIV-infected children receiving ART in western Kenya. Interviews covered multiple aspects of the
experience of having children take medicines. Transcribed interview dialogues were coded for analysis. Data
were collected from 120 parents and guardians caring for children 0–14 years (mean 6.8 years, standard devi-
ation [SD] 6.4); 118 of 120 had not told the children they had HIV. Children’s caregivers (parents and guardians)
described their views on disclosure to children and to others, including how this information-sharing impacted
pediatric ART adherence, children’s well-being, and their social relationships. Caregivers believed that disclo-
sure might have benefits such as improved ART adherence, especially for older children, and better engagement
of a helping social network. They also feared, however, that disclosure might have both negative psychological
effects for children and negative social effects for their families, including discrimination. In western Kenya,
caregivers’ views on the risks and benefits to disclosing children’s HIV status emerged a key theme related to a
family’s experience with HIV medications, even for families who had not disclosed the child’s status. Assessing
caregivers’ views of disclosure is important to understanding and monitoring pediatric ART.
Introduction
Antiretroviral therapy (ART) saves the lives of HIV-infected children.1–7 For the 2.3 million children around
the world currently living with HIV, initiating and main-
taining ART is crucial to slowing their progression to AIDS
and preventing deaths.8,9 Ninety percent of the world’s HIV-
infected children live in Africa,8 often in resource-poor set-
tings with limited treatment options. In these settings, it is
especially crucial to determine factors that enhance or hinder
the provision of ART to children.
The caregivers of HIV-infected children, whether parents,
relatives, or other guardians, play a crucial role in the provi-
sion of ART to children. Children are usually dependent on
adults to receive effective HIV therapy; to varying degrees,
children may require that adults give them their medications,
access the clinical care system, and obtain medication refills.
In this context, disclosure of HIV status plays a unique role in
the interactions of children and adults around HIV medica-
tions. Whereas adults generally know why they are taking
their medications, control their own medication usage, and
have some sense of the importance of adherence, many
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HIV-infected children have not been explicitly told of their di-
agnosis or why adherence to their medications is important.10–13
Disclosing a diagnosis of HIV to the child presents a unique
challenge for maintaining appropriate ART for children. In
some settings, children’s awareness of their HIV status has
been associated with the quality of adherence to ART. In a
study from Maryland, children who were aware of their HIV
status were significantly less likely to be categorized as ad-
herent.14 In a study from New York, children’s knowledge of
their HIV status was also associated with lower CD4 counts
and higher viral loads.15 In another study of HIV-infected
children in New York, adherence was not significantly asso-
ciated with the child’s awareness of their diagnosis, but less
disclosure to other people or less social disclosure was sig-
nificantly associated with increased nonadherence.16 Despite
these studies connecting disclosure to children with non-
adherence, the perception of many pediatric health care pro-
viders is that disclosure helps children understand the need
for ART and creates a trusting relationship that facilitates
adherence.17–19 A small qualitative study examining pediatric
adherence in Belgium found that, in some cases, disclosure of
HIV status was necessary to overcome the child’s opposition
to taking the HIV medications; however, disclosure to the
child led to better adherence only when the caregiver was also
adherent to their own ART.20
Most of the current understanding of how children’s
awareness of their HIV diagnosis on impacts their adherence
to long-term ART is drawn from work in resource-rich set-
tings. In resource-limited settings, neither the perceived im-
pact of disclosing a child’s HIV status, nor the actual impact of
disclosing a child’s HIV status is well described. Emerging
studies among developing pediatric care systems show that
many HIV-infected children are not aware of their HIV status.
One study from Thailand reported that only 1 in 5 HIV-
infected children ages 5–16 years (mean age, 9.6 years) had
been told of their HIV diagnosis.10 A cross-sectional study
from the same country showed that, among children ages 6–
16 years (average age, 9.2 years), 30.1% of the children knew
their HIV status.13 In both studies, disclosure was perceived to
carry certain risks. Parents raised concerns about disclosure to
a child psychologically harming the child.10,13 Other reasons
for not disclosing to children included concerns that the child
was too young and that the child could not keep a secret.10
In sub-Saharan Africa, research describing factors effecting
disclosure of a child’s HIV status is just emerging. Studies
from South Africa using semistructured interviews suggest
that caregivers and health care providers are concerned about
how the disclosure of pediatric HIV infection might impact
medication adherence.21,22 In the Democratic Republic of the
Congo, a qualitative study with 19 youth and 21 caregivers
found that the median age at disclosure was 15 years, and one
of the most common reasons for disclosure was to improve
the child’s adherence to their treatment regimen, as well as the
child’s need to stay healthy or to protect herself/himself.23 In
a qualitative study with 42 pediatric caregivers in Uganda,
complete disclosure of pediatric HIV status to children ages
5–17 years (median, 12 years) was related to good ART
adherence.24 There are data to suggest that both disclosure to
children and disclosure to others may affect important aspects
of therapy such as adherence. In another Ugandan study,
which used a standardized questionnaire to assess adherence
and disclosure, not disclosing the child’s status to anyone
other than the primary caregiver was associated with pedi-
atric nonadherence, but disclosure to the child was not
associated significantly with adherence.25 In a larger cross-
sectional study from Ethiopia, children who did not know
their own HIV status and children who were not aware of
their caregiver’s health problems were actually more likely to
adhere to ART than their counterparts, even when adjusting
for other characteristics such as age.26 A cross-sectional sur-
vey of 127 HIV-infected adolescents in Zambia found high
rates of emotional and peer problems among the group, but
disclosure of HIV status was not associated with worsened
mental health.12 Thus, existing studies examining the rela-
tionship of disclosure of children’s HIV status to ART ad-
herence suggest that the effects of disclosure may vary from
one setting to another.
How pediatric caregivers communicate with their children
or with others, particularly about issues related to HIV, may
impact both disclosure and adherence. A qualitative study
from the Democratic Republic of the Congo suggests that
patterns of limited communication between caregivers and
children greatly impacted the experience of disclosure, mak-
ing it more of a discrete event than a process.27 Therefore,
understanding how pediatric caregivers in a given setting
view the sharing or withholding of information about a
child’s HIV status, either to the child or to social others, may
shape the delivery of pediatric HIV care in that setting, in-
cluding how to facilitate disclosure and how to maintain ART
adherence.
Qualitative research methods offer a way to explore care-
givers’ perceptions, choices, and patterns of behavior in a
particular setting.28–30 In grounded theory, a qualitative re-
search method, a theoretical framework to describe a pattern
of behavior is derived from the systematic analysis of indi-
vidual interviews or focus group discussions.31,32 We used a
grounded theory approach to describe how a sample of pe-
diatric caregivers in western Kenya view the disclosure of a
child’s HIV status and how these perceptions of disclosure
might impact pediatric ART adherence.
Methods
Setting
This study was conducted in western Kenya within the
USAID-Academic Model Providing Access to Healthcare
partnership (AMPATH). AMPATH grew out of a partnership
established in 1989 between Indiana University School of
Medicine, Moi University School of Medicine, and Moi
Teaching and Referral Hospital (MTRH).33 Since 2001, AM-
PATH has been a model HIV care system for resource-limited
settings.33,34 The AMPATH clinical care system operates in
Kenya, a country with a national HIV prevalence of 7.8%,
where over 1.4 million persons live with HIV, including
150,000 children.35 As of February 15, 2010, AMPATH has
enrolled more than 111,404 patients in western Kenya, and
currently follows more than 68,740 active patients (including
more than 14,603 children) at 23 urban and rural clinic loca-
tions and 23 satellites. AMPATH provides free antiretroviral
therapy (ART) to all patients qualifying for therapy, as well as
comprehensive nutrition services, psychosocial support, and
economic development training.
This study was conducted within four representative
AMPATH clinics. One site was the urban referral center in
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Eldoret, which has been in operation since November 2001 on
the grounds of MTRH. As of April 15, 2010, the MTRH clinic
currently cares for a total of 22,537 patients. Of those patients,
4618 are children 14 years of age or younger, and 1,052 chil-
dren at MTRH are currently on ART. The three rural locations
were the Chulaimbo Provincial Rural Health Training Centre,
Burnt Forest Rural Health Centre, and Mosoriot Rural Health
Centre. The Chulaimbo clinic currently cares for 1865 chil-
dren, with 360 on ART. Burnt Forest clinic cares for 654 chil-
dren, with 164 on ART. Also, the Mosoriot Rural Health
Centre cares for 1054 children, with 192 on ART.
Research design
Focus groups and individual interviews were used to
elicit data from parents and caregivers of HIV-infected
children taking ART through the AMPATH care system.
Information on the process of medicine-taking, barriers and
supports to maintaining ART, and beliefs about disclosure
of HIV status were queried. An overview of the factors
sustaining pediatric ART adherence in this setting has been
published elsewhere.36 This analysis focuses on the cross-
cutting theme of disclosure or information-sharing and the
participants’ dialogue related to that theme. We used both
focus groups and individual interviews in order to garner
the benefits of both techniques, so that a more compre-
hensive understanding could be achieved. The group dis-
cussions allowed for amplification of the shared
perspectives and themes,37,38 while the individual inter-
views potentially lessened biasing effects from social
norms.30 Participants in both the focus groups and the key
interviews met the same inclusion criteria; they were all
parents of HIV-infected children on ART through AMPATH.
The focus groups and interviews were conducted in Kis-
wahili, one of the two national languages in Kenya. The
groups and interviews were conducted between March 1 and
November 30, 2007 by a trained facilitator who was not part of
the clinical care system. A prepared interview guide, con-
taining open-ended questions, was used to solicit responses
during a 2-h session for focus groups and a 1-h session
for individual interviews. Questions were based upon review
of the literature, the input of local health care providers, and
pretesting with a series of five, in-depth key informant inter-
views conducted within subjects’ homes. The final questions
covered multiple areas related to the experience of caring for
HIV-infected children ART. The interview guide covered the
cultural context of HIV treatment, including treatment deci-
sion-making, cultural reactions; disclosure, including disclo-
sure to other people and to children, and beliefs about
disclosure; medication handling, which included questions
about travel and water practices; beliefs about medicines;
interactions with children around medicines; and barriers to
medication adherence. As examples of the questions about
disclosure, participants were asked the following: ‘‘What do
you think about telling other people that your child has HIV?’’
and ‘‘How do you feel about giving your child medicine for
HIV in front of others?’’ Other questions focused more gen-
erally on the family’s social context: ‘‘Caring for a child who is
infected with HIV can be very difficult. Many parents tell us
that it is more difficult when family members or others in their
community or in their village do not support them. How is it
for you in your community?’’ [Complete focus group and
individual interview guides available from the corresponding
author on request.] The same interview guide was used for
both the focus groups and individual interviews, with some
additional questions added to the guide through the course of
data collection in following a grounded theory approach. All
data regarding the caregivers and their children were based
on the participants’ self-reports. All of the participants gran-
ted permission to digitally record the sessions to allow for
later transcription. Field notes were also taken during and
immediately after the encounters. All of the recordings were
transcribed and translated into English by a trained translator.
Translations were checked for face validity by a bilingual
study investigator (W.M.N.).
Participants
Parents and caregivers of HIV-infected children on ART
were recruited from within the AMPATH care system. Chil-
dren whose parents or caregivers were eligible for participa-
tion were identified through a search of the AMPATH
electronic medical record system. Fliers were placed on the
charts of eligible patients, encouraging clinicians to refer them
to the study team. Fliers were also placed around the clinic
and in exam rooms to allow for self-referral into the study.
Female parents and caregivers were selected based on a
convenience sample; however, male caregivers were pur-
posefully oversampled in order to include this minority
population, which makes up only 8% of the primary care-
givers for children. Inclusion criteria involved being a parent
or primary caregiver of an HIV-infected child on ART through
AMPATH. There was no minimum duration of time for the
children to be on ART, nor was purposeful sampling done on
the basis of disclosure practices. The AMPATH pediatric
clinics only care for children up the age of 14 years, so parents
and caregivers were identified based on HIV-infected chil-
dren less than 14 years of age. Parents may or may not have
been HIV-infected or been on ART themselves. Parents or
caregivers were excluded from participation only if they had a
mental or physical impairment preventing them from being
able to give informed consent. Parents and caregivers of
children under the age of 5 or 6 years of age were included to
provide a broad picture of how caregivers perceive disclosure
to other people and to children throughout the child’s de-
velopmental course and to provide a more representative
cross-section of our enrolled population. Participants were
randomly assigned to focus group versus the individual in-
terviews and offered a focus group date or interview date
accordingly. However, if a participant assigned to a focus
group was not able to attend on the date of a scheduled focus
group, they were then offered the option of scheduling an
individual interview. We conducted four focus groups at the
urban referral center in Eldoret, Kenya, and six focus groups
at three more rural HIV clinics, with a total of 85 participants
in the focus groups. Focus groups were divided by gender.
One focus group with exclusively male caregivers was done
at the urban referral center. At the rural health centers, all of
the male caregivers were interviewed individually, and the
focus groups contained only women. In addition, we con-
ducted 35 individual interviews. We enrolled participants
until thematic saturation was reached. All participants gave
witnessed, verbal informed consent based on a written in-
formed consent document prior to participating in the study.
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Participants received a modest honorarium to defray the time
and transportation costs of their participation.
Analysis
A system of manual, progressive coding of the transcripts
was used to identify emerging central concepts.31,32 The initial
stage of constant comparative analyses was done through
open coding by two investigators (R.C.V. and E.G.W.), in-
volving a line-by-line analysis of each transcribed page of
informant data to elucidate meanings and processes. These
analysts also independently extracted and compared themes.
Both the open codes and the themes extracted by the two
analysts revealed high degrees of agreement between the re-
viewers. Cohen’s k was 0.78, indicating substantial agree-
ment.39 Before condensing the codes, three analysts read the
data several times, including comparison of a final review of
all open codes from each of the analysts, followed by recoding
based on consensus by the three analysts (R.C.V., E.G.W.,
W.M.N.). We then did axial coding, the process of relating
categories to their subcategories and linking them together at
the level of properties and dimensions,31,32 to organize the
themes into their causal relationships. Hypotheses and con-
cepts were developed inductively from the data. Finally, re-
lationships among the codes were integrated, refined, and
diagrammed in the development of a contextualized, theo-
retical framework to describe HIV-related child care in this
resource-limited setting (unpublished data). Selected quota-
tions were used to illustrate key themes.
Triangulation or verification was incorporated on several
levels, using accepted techniques to ensure the validity of
qualitative data.40,41 First, we analyzed and compared tran-
script data from two sources: the focus groups and the key
informant interviews. Second, independent reading, coding,
comparison, creation of figures for concepts, and data visu-
alization were performed by three investigators (R.C.V.,
E.G.W., W.M.N.). Finally, we incorporated two sources of
peer debriefing and peer checking of transcripts, coding
strategies, themes, and diagramming of relationships
(D.G.M., T.S.I.). For the peer debriefing, these two additional
investigators reviewed the field notes, a subset of the tran-
scripts, and discussed development of the coding strategies
and emerging themes. The peer debriefing and peer checking
primarily refined the organizational structure and conceptual
map created from the data, refining the organization of the
causal relationships and confirming the prominent themes.
Regulatory Approvals
This study was approved by the Institutional Review Board
of Indiana University in Indianapolis, Indiana and by the
Institutional Research Ethics Committee of Moi University
School of Medicine and Moi Teaching and Referral Hospital in
Eldoret, Kenya.
Results
Study participants
Data were collected from 120 parents and caregivers of
HIV-infected children on ART, including 21 males and 99
females. Eighty-five parents and caregivers participated in the
10 focus groups and 35 in individual interviews. The partici-
pants, who ranged in age from 18 to 84 years, were repre-
sentative of all local major ethnic groups in the area, including
Kalenjin, Luhya, Luo, Kikuyu, and Kisii. Of the caregivers,
17.5% were male. Of these caregivers, 42% were not parents of
the children, but were other relatives or nonbiological
guardians. The parents and caregivers provided care to 123
children on ART who ranged in age from 0 to 14 years (mean,
6.8 years of age; standard deviation 6.4). Thirty children were
0–3 years of age, 30 were 4–6 years, 42 were 7–10 years, and 20
were 11–14 years (with age missing for 1 child). All of the
children were presumed to be infected perinatally with HIV
although one child had also had a blood transfusion prior to
diagnosis. The children had been diagnosed with HIV for
between 1 month and 8 years (mean, 2.7 years), and had been
on ART for time periods ranging from 1 month to 4 years
(mean, 1.9 years).
Antiretroviral therapy adherence
Parents and caregivers commonly reported difficulties with
medication-taking. In the focus group discussions, 87 adher-
ence problems were reported by group participants (range,
5–17 per group). Nineteen of the 35 interview participants vo-
lunteered problems they had experienced with ART adherence.
The most commonly cited problems with medication adher-
ence included delaying or skipping doses because they did not
want to give the child medicines in front of others, the caregiver
just forgetting to give the medicines when busy, having diffi-
culty traveling to the clinic to get the medicines, not having
food to give the child with the medicines and thus skipping
doses, and not being able to give the medicines because the
only caregiver who knew about the medicines was away.
Caregiver disclosure of the child’s
HIV status to the child
Disclosure of the child’s HIV status was an important and
common theme throughout the qualitative inquiry, with care-
givers expressing their beliefs about and perceptions of disclo-
sure as a central theme to the experience of having a child on
ART (Table 1). Although disclosure was frequently discussed,
most of the pediatric caregivers had not told the child that they
had HIV. Only 2 of the 120 caregivers reported having told the
child why they were taking ART. In both cases, these caregivers
were grandparents of children whose mother and father had
both died from HIV. Both children who had been told of their
diagnosis were 14 years of age at the time of the interview; one
had been 13 at the time of disclosure, and the other was 14 at the
time of disclosure. Older or ‘‘big’’ children were generally cat-
egorized as those 11- to 12-years-old and above. ‘‘Small’’ chil-
dren were seen as those under the age of 6 or 7 years. Children
in between 7–11 years were typically seen as being too young to
know their diagnosis, but old enough to begin taking some
responsibility for their medications and old enough to start
asking questions about why they were taking the medicines.
Caregivers viewed disclosure as having the child know ‘‘why
they are taking the medicines.’’ Some parents and caregivers
reported that they had begun partial disclosure by telling the
children the general purpose of their medicines, such as that the
medicines ‘‘stop [him or her] from being sick again,’’ without
mentioning HIV specifically. Caregivers did not consider this
the same as the child knowing why they were taking medicines.
Many caregivers also reported that they had told the children
that they needed the medicines for other reasons, such as a
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‘‘chest problem’’ or a ‘‘stomach problem,’’ and felt that lying to
the child about why they needed medicines was not bad.
Benefits of disclosing child’s HIV status to the child
Disclosure to children was viewed as having potential ben-
efits for maintaining pediatric ART adherence (Table 1). Parents
and caregivers suggested that disclosure to children could im-
prove pediatric adherence as children became older. These
older children would then better be able to take responsibility
for their medications. The parents and caregivers reported that
the converse was true; parents and caregivers reported that
children not knowing they have HIV becomes a barrier to ART
adherence as time goes on. Specifically, nondisclosure becomes
a problem for getting the children to take their medicines as they
get older and begin to ‘‘ask questions.’’ The child not knowing
why they were taking the HIV medicines was cited as a pro-
minent challenge for medication adherence:
Disclosure is a problem [for adherence]. My child has not
reached the stage of asking the reason for them swallowing the
drugs because he is still young. There are some whose children
ask, ‘‘Why am I swallowing the drugs?’’ (Focus group, mother
of 5-year-old)
‘‘One challenge is wih the big children. I don’t see a problem
with the small ones because they are given and they take [the
medicines], but when they reach a certain age, and they start
asking themselves, ‘‘Why do I take medicine in the morning
and in the evening?’’ . . . This is where we as caretakers have a
problem. The problem is when this child starts getting wise
and starts asking why they are taking these drugs. (Focus
group, grandmother of 13-year-old)
Fears of negative effects from disclosure to children
Although the participants felt that informing the child why
they were taking the medicines might reduce these questions
and help with adherence, they also reported that they feared
negative effects from disclosure. For some, these fears seemed
to be what prevented them from telling the child about their
HIV status. The major concerns about disclosure for caregiv-
ers in Kenya included the following: fear of adverse psycho-
logical consequences for the child, believing the child was not
developmentally ready to understand the implications of the
HIV diagnosis, and wanting to avoid the child’s subsequent
disclosure to other people.
The caregivers frequently described that disclosure
might have negative psychological consequences for the
child, such as children being ‘‘affected’’ or ‘‘having lots of
thoughts.’’ More emotional components of depression or
anxiety, such as being sad, crying, or worrying, were not
mentioned. The potential psychological consequences of
disclosure were described primarily with their cognitive or
behavioral components. The feared psychological conse-
quences were described as concerns that the children would
be ‘‘thinking and thinking’’ and ‘‘refuse to play with other
children’’ and ‘‘lose their memory.’’ The caregivers did not
describe the children losing hoping or becoming depressed
or anxious in emotional terms, but instead described cogni-
tive components of these conditions such as repetitious
thoughts or becoming forgetful. Other symptoms of mental
health challenges, such as withdrawing from others, were
also described.
Table 1. Perceived Impact of HIV Disclosure to Children and to Others
Perceived impact Illustrative quotes
Disclosure
to children
Benefits:
Improved adherence for older children
‘‘I had to tell her about her condition and that is when she had the
courage of taking [the medicine].’’
(Interview, grandmother of 14-year-old describing improved
adherence after disclosure)
Increase in child’s responsibility
for medications
Risks:
Adverse psychological consequences
‘‘If the child knows and they are naughty and you call them to
take the drugs, they may tell the other children, ‘I am taking
drugs because I have AIDS.’ So, the other children run to tell
their mothers and report what the child has said.’’
(Focus group, mother of 7-year-old describing fear of child
disclosing to others, leading to feared stigmatization)
Disclosing before developmentally ready
Child’s subsequent disclosure to other
people leading to discrimination
Disclosure
to others
Benefits:
Engage supportive network
‘‘When I came to [the clinic], my [family] brought me. My mother,
[the child’s grandmother], told my uncle, who helps me. She
told him that I have HIV. If I tell people, they will be talking
about me and gossiping. They will laugh at me. It is my
secret . . .But my uncle, he assists me. When I am not there,
my uncle’s wife gives [the child] the medicines.’’
(Interview, mother of 5-year-old, describing her supportive
family network)
Support in child care
Receive help
Eliminates need to hide the child’s
medications or delay doses
Risks:
Isolation
‘‘When they discover that you have it, they will obviously separate
you. You will have to fend for yourself. When I discovered my
child’s status, I was staying with my brother. When we knew our
conditions and told him, he chased us away. Whoever knows will
automatically separate you. If I die, there will be no one to care for
my son and it will also force him to die.’’
(Interview, mother of 4-year-old describing experience of
discrimination)
Stigmatization
Discrimination
Exposure to negative attitudes
toward HIV treatment that might
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Although caregivers felt that ‘‘big’’ children were more
prone to nonadherence in the face of nondisclosure, the
caregivers questioned whether even the ‘‘big’’ children had
the developmental readiness to understand and cope with
their diagnosis. Parents and caregivers typically defined being
‘‘big’’ as ‘‘reaching the age of 11 or 12 years,’’ and this was
typically regarded as the age at which full disclosure should
occur. The caregivers frequently expressed that they were
waiting to inform the child of their HIV status until the child
was older or more mature:
At the age of twelve, I will sit with him and look for someone who will
explain it all to him . . . at that age, his mind will be mature and he
will be able to understand what is going on, but at the age that he is
now, if you start explaining it to him, he will start wondering and
utter statements like ‘‘the way I have heard, that AIDS kills, it means
I will also die.’’ I feel that he is still young.’’ (Focus group discussion,
mother of 10-year-old)
Even among these ‘‘big’’ children, concerns remained about
their readiness for disclosure. One grandmother of a 12 year
old expressed the concern that if she disclosed to the child
who was ‘‘getting wise and start[ing] to ask why they are
taking these drugs,’’ it would be like ‘‘the grandfather or
grandmother has killed the child’s thoughts.’’ ‘‘Kill[ing] the
child’s thoughts’’ was used as a cognitive description of losing
hope or being depressed, in which the child stops thinking of
the future or having hope for the future. The caregivers felt
that disclosure must be done as a process, ‘‘slowly by slowly
until you know that she or he has understood why they are
using that medicine,’’ and they emphasized that even the
‘‘big’’ children might not be ready for this.
Caregivers were very concerned about avoiding the child’s
subsequent disclosure to others. They strongly emphasized
that they did not want to tell the child about their HIV status
for fear that the child would tell others that they had HIV, and
that negative social reactions, such as increased stigma or
discrimination, would result:
If they know, the questions might be more than that, because
[the child] may ask you, ‘‘How did I get this disease? How was
it?’’ And the child goes to announce to others that he has this
disease, and he may spoil everything. This is what disturbs
parents and it may be a barrier to taking [the medicines].
Telling your child that they have HIV. (Focus group, mother of
9 year old)
I don’t know how [other people] will take it, so I don’t tell the child.
I fear they may segregate him. (Interview, aunt of 14 year old)
Caregivers wanted to avoid this additional disclosure be-
cause they were concerned about the potential negative effects
for the child and for the family. They expressed concern that
children would hear from others that people with HIV ‘‘won’t
get well and will die,’’ or that the children would learn from
others that the HIV ‘‘came from your parents.’’ This suggested
concerns that disclosure could impact the child’s psycholog-
ical state, resulting in a lack of hope, but also that family
relationships might be damaged. Parents and caregivers re-
peatedly expressed fears that the child’s self-disclosure to
others might reveal the mother’s HIV status, but they were
most concerned that disclosure ‘‘may spoil everything’’ be-
cause the community’s knowledge that HIV was present in
the family might result in isolation and discrimination. The
caregivers deeply feared isolation and stigmatization of both
the child and the family, fearing that the other children would
‘‘refuse to sit with [the HIV-infected child]’’ and that the HIV-
infected children would ‘‘be alone’’ and the family ‘‘would
receive no help.’’
Caregiver disclosure of the child’s HIV status to others
Caregivers suggested that disclosing a child’s HIV status to
other people could result in benefits for shared childcare,
sustained adherence, and community support. However,
many participants also believed that disclosure to others
could result in negative effects, depending on whether the
attitudes and beliefs of those receiving this information were
negative or positive (Table 1). Among the 99 participants who
described which people knew that the child took medicines
for HIV, 13.1% reported that they had told no one else, 25.3%
reported telling only one other person, 16.2% had told 2 other
people, 10.1% had told 3 other people, and 35.3% had told
more than 3 people or told an unspecified number of people
(e.g., ‘‘those who live in the household’’ or ‘‘my whole family’’).
Based on the 120 persons reported to know that the child was
taking medicines for HIV, 28.3% of those who knew were the
siblings of the parents or caregivers, 24.2% were the caregiv-
er’s spouse or the parent of the child, 20.8% were the grand-
parent of the child, 15% were neighbors or friends, 10% were
siblings of the HIV-infected child, and less than 1% were
house help or teachers of the child.
Benefits of disclosing a child’s status to others
In the cultural context of western Kenya, caring for children,
including sustaining ART adherence, usually involves the
support of a network of family and community members.36
Engaging this network of family and community members may
require some degree of information-sharing, particularly re-
garding what needs the family has. For a family with HIV-
infected members, engaging the social network may require
disclosure about a child’s HIV status or about their need to take
medications. Parents reported that disclosure to others could
result in a positive response, engaging this supportive network
and allowing the caregivers to receive support in child care,
including help in maintaining ART adherence for the child. The
mother of a 5-year–old girl describes how informing family
members about the child’s diagnosis and ART allows them to
assist in administering the medicines:
I usually give [the medicines] and also the child’s aunt gives
some other times, and we don’t fear because we all know what
the disease [is]. The family members around know what the
drugs are for, and I have explained to them such that when it
reaches time, even if the child is asleep, we usually wake them
up to take the medication. (Focus group, mother of 5 year old)
Negative impact of not disclosing to others
In contrast, caregivers who do not disclose to others report
that they ‘‘lack help.’’ Nondisclosure to others makes child care
more difficult because caregivers do not have other people who
can support them or assist with administering the medications:
There is no one. I just depend upon myself . . . we are just on our
own. (Focus group, mother of 6 month old)
I have difficulty some times when I have left. Sometimes I am
not near and I tell the children to give the child the medicine
and when I come I find they have forgotten. They didn’t give
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the child medicine yesterday so there is that difficulty. (Focus
group, aunt of 6-year-old)
It was hard. It was just me and my boy alone. I had to ensure
that he had taken his medicine, stay with him, and give him
milk because he had TB.’’ (Interview, mother of 14-year-old)
Not disclosing the child’s diagnosis to other people rein-
forces caregivers’ feelings that they need to hide the diagnosis
or to hide the child’s medicines from others. In this cultural
setting, in which people often live in compounds with limited
privacy, concealing an HIV diagnosis and HIV medications is
not easily maintained and can interfere with taking the
medications on time or taking them every day. The presence
of household members or neighbors who did not know the
child’s diagnosis was frequently cited as a cause of missed or
late doses of ART:
Some people fear because they have not disclosed to their
husbands that the children are sick, so they can’t give medicine
when the husband is there. (Interview, mother of 7 year old)
Someone can even come to my house and I will just sit. I can
even delay giving the medicine for an hour [until] that the
person leaves. (Focus group, mother of 5 year old)
Others fear other people, colleagues, and friends. The fact that
there is a person near who doesn’t know that they are taking
drugs makes them not want to be seen swallowing the medi-
cine or to be associated with it.’’(Focus group, mother of 2 year
old)
In contrast, disclosing the diagnosis to others might allow
the caregiver more freedom in administering the medications,
and might lead to better adherence.
Fears related to disclosure to others
Although disclosing the child’s diagnosis to others could
allow caregivers to receive help, to give the medications
more freely, or to sustain adherence, the caregivers also feared
the potential negative consequences of disclosure to others.
The majority of parents and caregivers chose not to dis-
close the child’s HIV status to other people because they
thought that sharing this information would result in being
isolated or stigmatized. The fear of isolation or stigmatization
led them, instead, to try to hide the medicines and everything
associated with the HIV diagnosis. The fears of isolation and
stigmatization are clearly reflected in the following excerpts:
Many times I have seen one thing. For example, when people
discover that a child has the virus they start isolating them.
They leave that child alone. Then, they tell their children not to
eat or share their food with the child who is infected. They
should not play with such a child. Don’t sleep with them, don’t
put on their clothes. So when such things happen, the child
begins to feel lonely and they wonder why. So many times,
grandparents like me can’t tell anyone, anyhow about the
status because they will not help. And if you tell them, others
will spread the information, so even going on a journey with
the child becomes a problem. (Focus group, grandfather of 13
year old)
If they discover that your child has the disease they will stop
their children from playing with your own. If you are in the
vehicle and they know that you have it, they move far away
from you. They say that this is a bad disease, and everyone
doesn’t like it. (Focus group, grandmother of 6 year old)
In addition to anticipating negative impacts from being
exposed to stigmatization and discrimination, caregivers ex-
pressed concern that disclosure to others might lead to non-
adherence because of the negative opinions many community
members hold towards the HIV medications. Caregivers ex-
pressed that exposure to the negative opinions of others, such
as the view that ART use is futile, might make them ‘‘lose
heart’’ and ‘‘leave the medicines:’’
If someone hears that you are swallowing these drugs, they tell
you that even if you take that medicine, you don’t get well.
‘‘This disease—you hear them announcing everyday that it has
no treatment. So, this is just wasting your time. There is no
need for you to fill yourself with drugs—stop taking!’’ That is
why many people stay in the state of hiding the medicine. They
don’t tell anyone because, you see, they will break your heart.
(Focus group, mother of 3 year old)
In summary, parents and caregivers of HIV-infected chil-
dren described how disclosure to others enabled them to en-
list the help and support of their family and neighbors, but
their fears of isolation, stigmatization, and being discouraged
from taking the medicines often inhibited them from dis-
closing the child’s HIV status to additional people. Choosing
not to disclose to other people may also compromise the
children’s adherence to ART when caregivers struggle to hide
the medicines from other people and do not receive support
and assistance from those in the immediate community or
household.
Discussion
Parents and caregivers of HIV-infected children on ART in
western Kenya described disclosing or not disclosing informa-
tion about a child’s HIV status as central to the experience of
having a child on ART. The caregivers’ views about disclosure
of children’s HIV status included perceived risks and benefits
for pediatric antiretroviral therapy adherence, child well-being,
and social relationships They perceived that informing children
of their own HIV status or disclosing the child’s diagnosis to
other people could sustain pediatric ART adherence through
addressing the children’s developmental needs to understand
why they are taking medicines or through engaging a sup-
portive network of helpers. However, they were simulta-
neously concerned about the risks involved with disclosing HIV
status, particularly the risks if others respond negatively by
stigmatizing, isolating, or discouraging the family or if the child
might be negatively affected by disclosure. Only two caregivers
had actually informed children of their HIV status; however,
more had disclosed the child’s status to other people. While
some of the caregivers were caring for children who were likely
too young or developmentally unready for disclosure, the low
rates of disclosure may stem from some of the caregivers’
concerns about the potential negative impact on the child or on
the family’s social relationships. Assessing caregivers’ disclo-
sure practices and views of the effects of disclosure is important
to the ongoing care of children on ART, particularly for un-
derstanding how the caregivers might interact with their chil-
dren and with their peers and how this might impact the child’s
HIV care over time.
The limited existing research from sub-Saharan Africa re-
veals that pediatric disclosure is a prominent concern among
families,22,42 but the perception of how disclosure might im-
pact emotional health or health behaviors such as adherence
are not clearly understood.12 Our findings provide a more
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detailed picture of how caregivers for children of varying ages
view disclosure and its impact in a particular cultural context
in Kenya. Qualitative work from other settings in sub-Saharan
Africa suggests that understanding the existing framework in
which children and caregivers communicate about health is-
sues is important to shaping the process of disclosure that will
follow.27 These findings from western Kenya suggest that
exploring caregivers’ perceptions of how disclosure will im-
pact the child’s care and adherence, the child’s psychological
well-being, and the child and family’s social relationships are
key to health care systems caring effectively for children.
These findings are similar to those found in qualitative work
from Kenya’s urban capital, in which potential societal dis-
crimination, lowered self-esteem, and concerns about confi-
dentiality featured prominently among adolescents’ concerns
with telling others about their HIV status.43 Similar views
and beliefs among pediatric caregivers can subsequently be
explored in other resource-limited settings, including sub-
Saharan Africa.
In addition to offering a description of the perceptions of
disclosure within the culture, our findings also suggested
ways that adherence to ART might be enhanced by a disclo-
sure process that informs children about their HIV status in a
developmentally appropriate manner. The idea that pediatric
adherence might be enhanced by disclosure is in keeping with
many studies from both resource-rich and resource-limited
settings.24,44 From the findings of this qualitative study, we
cannot conclude whether disclosing a child’s HIV diagnosis,
either to the child or to other people, will improve pediatric
ART adherence. However, our data do suggest ways in which
disclosure could improve adherence, and what benefits to
disclosure resonate with caregivers in western Kenya. Dis-
closure can allow older children to understand why they are
taking daily medications and to begin to assume responsi-
bility for their medical care. Disclosing the child’s HIV diag-
nosis to even one or two supportive adults may create a
context in which the priority can shift from hiding the medi-
cations to taking the medications routinely. Moreover, having
at least one other adult who knows about the medications
may enable the caregiver to receive the help and support that
they need to provide consistent care to the child.
Parents’ and caregivers’ fears related to the negative impact
of disclosure on the child’s psychological state were common
in this study, and have also been commonly reported in other
studies of parents’ beliefs and fears about disclosure.10,13,45
However, evidence from both resource-rich and resource-
limited settings suggest that rates of depression, anxiety, and
emotional and peer problems are no higher among children
who have been informed of their HIV status.46–48 This existing
evidence may be useful in allaying caregivers’ fears about the
impact of disclosure on the child’s mental health. While the
fears of subsequent disclosures of HIV status and resulting
negative social responses have been reported in other stud-
ies,10,43 we could not locate any literature evaluating whether
disclosure to children does indeed increase the amount of
stigma and discrimination that families experience. This
suggests that stigma, isolation, and discrimination should be
monitored closely when evaluating programs to increase pe-
diatric disclosures. Understanding how caregivers in this
setting perceive the benefits and risks of disclosure of a child’s
HIV status enables clinicians and care systems to address
these fears and to open dialogue about how, when and
whether to undertake disclosure. Understanding the per-
spective of these parents and caregivers helps clinicians and
health care systems to formulate appropriate strategies to
support them in the process of disclosure and prepares eval-
uators and researchers to measure appropriately any positive
or negative effects of disclosure.
The analyses included very few parents or caregivers who
had actually disclosed to this child, with only 2 of the 62
children older than 7 years having been informed of their HIV
status (3.2%). Among the younger children, it is not unex-
pected that the children would be considered developmen-
tally immature or too young to be informed about their HIV
status. Even among the older children, these low rates do not
seem atypical for this region. Unfortunately, we do not yet
have true population-based data from our setting to charac-
terize rates of disclosure to children. Interviews with health-
care providers in western Kenya for the purpose of disclosure
training suggest that only a small number of children have
been told about their status, and that this does not typically
occur until age 12 or 13 years at the earliest. Possible factors
related to these low disclosure rates could include the fears
about negative impacts from disclosure, other cultural beliefs
related to the view of children,49 or the fact that no systematic
program to facilitate or promote disclosure was currently in
place within the HIV care program.
Strategies to support pediatric disclosure in health care
systems in resource-limited settings should incorporate local
perspectives into the entire disclosure process. The process of
disclosure involves multiple steps over the child’s develop-
mental course, including gathering information about the
family, preparing and educating the parents or caregivers
about relevant health literacy and the benefits and drawbacks
to disclosure, assessing the child’s developmental stage, and
the proceeding through partial and full disclosure. In ad-
dressing many of the fears raised by parents and caregivers in
this setting, it is important to remember that partial disclo-
sure, in which a child is given some, but not all of the infor-
mation about their diagnosis, could be an important first step
for younger children or in settings where families face the
risk of significant discrimination. Moreover, postdisclosure
counseling to address feelings, reactions, and family and
community dynamics is a vital part of the disclosure process.
This study does have limitations that merit consideration.
The results rely on the contextual data and lived experiences
of participants in a very particular part of the world—four
clinics in western Kenya. The results may not generalize to
other geographic locations. Furthermore, the focus group
methodology has the inherent limitations of using small,
convenience samples that can limit the generalizability. The
lived experiences of participants in this particular resource-
limited setting, on the other hand, may have more general-
izability for caregivers in other resource-limited settings than
do similar studies conducted in resource-rich settings. Other
aspects of the study population were fairly heterogeneous; it
included both biological and nonbiological caregivers, care-
givers from urban and rural settings, and care being provided
to children ranging in age from infants to adolescents. While
this may make it difficult to determine the relative views on
disclosure for different ages of children or different types of
caregivers, it offers a broad perspective on how caregivers of
children perceive disclosure throughout childhood. The par-
ents or caregivers of very young children would be very un-
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likely to have disclosed the HIV status to their children;
however, we were able to gather their descriptions of how
they viewed this future event and how they viewed disclosure
to other people. The study population included more female
caregivers than males; however, this does reflect the popula-
tion providing the majority of childcare within western
Kenya. Health behaviors such as actual adherence were not
measured, nor were parents and caregivers specifically asked
about their own adherence, so other measures of health be-
havior or belief cannot be compared with the behaviors and
attitudes reported in the focus groups and interviews. Because
the research focus was to understand any difficulties in the
care of HIV-infected children in this setting, confidentiality
was prioritized within the group and participants were re-
assured that their own behaviors would not be investigated or
reported. Because of this emphasis on confidentiality within
the group discussions, it is possible that more accurate reports
of difficulties with things like medication adherence were il-
luminated. While other analyses of adherence within the
study population, based on the self-report or caregiver-
reports given during clinic visits, reveal very high rates of
perfect adherence,50,51 the parents’ and caregivers’ relatively
frequent admissions of nonadherence within the focus groups
and interviews may actually reflect a more accurate picture of
pediatric adherence than what is available from the clinical
data. Finally, because so few of these parents and caregivers
had informed their children of the child’s diagnosis, the data
had only a limited ability to describe the impact that disclo-
sure actually had on the family and their health behaviors;
however, there is ample data related to their concerns re-
garding disclosure. Understanding the caregivers’ perspec-
tives on sharing pediatric HIV status with the children or with
others provides the first step in assessing the actual impact on
these families.
Recommendations for Clinicians
Although developmentally appropriate disclosure of HIV
infection to children is widely encouraged by organizations
such as the American Academy of Pediatrics,52 there are few
specific recommendations to guide clinicians who want to
carry out disclosure to children, particularly in resource-
limited settings.19,21 Moreover, it is possible that disclosure to
children or to others could carry real risks for families in some
settings; certainly this is the perception of many caregivers
and parents in western Kenya. These data, which emerge
from the lived experiences of caregivers in a resource-limited
setting, can inform clinicians caring for HIV-infected children
as to how to open dialogue with families about disclosure.
Based on the important challenges associated with disclosure
to children and disclosure to others, clinicians could begin by
asking caregivers who else knows about the child’s diagnosis
or knows that the child is taking medicines. Routine assess-
ment of who else knows about the medicines may provide a
valuable tool for assessing the context in which pediatric ART
adherence does or does not take place. Enhancing the support
system for caregivers may take the form of asking the care-
givers if they can identify even one or two other people to
whom they could disclose the child’s HIV status. Concerns
and fears related to disclosing could then be discussed and
possibly addressed. If caregivers are willing to disclose to
others, clinicians or dedicated disclosure counselors within
clinics could offer to participate as facilitators of disclosure to
extended family members or others. Families who have cho-
sen nondisclosure to others may benefit from alternatives to
strengthen their social networks, such as referrals to psycho-
social support or peer support groups in which they can re-
ceive peer support from other persons living with HIV or from
other caregivers of children with HIV.
Clinicians also need to guide the process of informing chil-
dren about their own HIV status. While disclosure to other
people can be limited across a child’s lifetime, children of in-
creasing maturity and understanding will need to be informed
of their diagnosis at some point. Well before the child begins to
raise questions about why they are taking medications, clini-
cians should open a dialogue with families about the process of
disclosure to the child. Ideally, disclosure would take the form
of an ongoing dialogue across many years of the child’s life,
informing them about more details related to their condition
and treatment as they get older. Prior studies have proposed
that receiving developmentally appropriate information about
HIV is key to pediatric disclosure and can even reduce chil-
dren’s emotional distress.44 In settings such as Kenya, attention
must be paid to the parent or caregiver’s concerns about the
child’s developmental readiness, any fears they have about the
subsequent effects of disclosure on the child’s psychological
and emotional state, and the perceived risks that ensue when
the child has the capability to disclose the HIV diagnosis to
other people. These challenges support the need for specifically
training clinicians or counselors in pediatric disclosure. More-
over, they should assist in the development, implementation,
and evaluation of culturally relevant, developmentally appro-
priate, and standardized materials to guide pediatric disclo-
sure. The age at which the process of disclosure begins should
be individualized based on the child’s maturity and the fami-
ly’s situation. However, setting a standard age at which to
begin disclosure may encourage clinicians to initiate routine
disclosure practices within the clinic.
Conclusions
In conclusion, clinical care systems must assess caregivers’
disclosure and their views of the effects of disclosure in order
to understand and maintain long-term pediatric ART. In-
creasing disclosure of the HIV condition to older children and
to other supportive adults may be important targets for im-
proving pediatric ART adherence. However, any efforts to
assess or increase disclosure, no matter how well intentioned,
must be sensitive to the concerns caregivers have about the
negative impacts of disclosure. Efforts to increase disclosure
must recognize, evaluate, and seek to minimize the very real
risks that families may take when they disclose an HIV di-
agnosis more widely.
Acknowledgments
This research was supported in part by a grant to the USAID-
AMPATH Partnership from the United States Agency for
International Development as part of the President’s Emer-
gency Plan for AIDS Relief (PEPFAR). The authors give special
thanks to the families and to the health care providers of AM-
PATH, including the nurses, clinicians, and pharmacy staff,
all of whom work tirelessly to ensure that the children of
Western Kenya receive the medications they need. In particu-
lar, we would like to thank Dr. Esther Nabakwe, Dr. Peter
PERCEIVED IMPACT OF DISCLOSURE OF PEDIATRIC HIV STATUS 647
Gisore, Dr. Sarah Wiehe, Dr. Constance Tenge, and the other
members of the AMPATH Pediatric Research Working Group.
R.C.V. led the conception and design, supervised the ac-
quisition of data, and participated in the analysis and inter-
pretation of data. She drafted the manuscript and led the
revisions. W.M.N. participated in study design, the analysis
and interpretation of data, and critical revision of the manu-
script. E.G.W. facilitated the acquisition of data, participated
in the analysis and interpretation, and participated in the re-
vision of the manuscript. S.O.A. participated in the study
design and the critical revision of the manuscript. D.G.M.
participated in the study design, supervised the development
of the interview guides and study protocol, participated in the
analysis and interpretation of data, and made substantial re-
visions and edits. TSI participated in the study design and
concept, supervised the development of the analysis strategy,
participated in the analysis and interpretation of data, and
offered critical revisions and edits. All authors read and ap-
proved the final manuscript.
Rachel C. Vreeman, M.D., M.S., is an assistant professor of
pediatrics in Children’s Health Services Research and in the
Ryan White Center for Pediatric Infectious Diseases in the
Department of Pediatrics at the Indiana University School of
Medicine in Indianapolis, Indiana, USA and co-director for
pediatric research for the USAID-Academic Model Providing
Access to Healthcare (AMPATH) in Eldoret, Kenya.
Winstone M. Nyandiko, M.B.Ch.B., M.M.E.D., is a senior
lecturer in the Department of Child Health and Paediatrics at
Moi University School of Medicine in Eldoret, Kenya and
associate program manager for AMPATH.
Samwel O. Ayaya, M.B.Ch.B., M.M.E.D., is a professor of
pediatrics in the Department of Child Health and Paediatrics
at Moi University School of Medicine in Eldoret, Kenya and
co-chair of the Moi University-ASANTE Kenya Pediatric
Research Working Group.
Eunice G. Walumbe, M.P.H., is a research assistant for
AMPATH in Eldoret, Kenya.
David G. Marrero, Ph.D., is the J.O. Ritchey Professor of
Medicine in the Division of Endocrinology and Metabolism in
the Department of Medicine in the Indiana University School
of Medicine in Indianapolis, Indiana, USA, as well as the di-
rector of the Diabetes Translational Research Center and di-
rector of the TRIAD Translational Research Center.
Thomas S. Inui, Sc.M., M.D., is the associate dean for Health
Care Research and the Sam Regenstrief Professor of Health
Services Research at the Indiana University School of Medicine,
as well as the president and CEO of the Regenstrief Institute.
The views expressed in this article are those of the authors
and do not necessarily represent the view of the Indiana
University School of Medicine or the Moi University School of
Medicine. The authors have no conflicts of interest to disclose.
The primary author had full access to all the data in the study
and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Author Disclosure Statement
No competing financial interests exist.
References
1. Doerholt K, Duong T, Tookey P, et al. Outcomes for human
immunodeficiency virus-1-infected infants in the United
kingdom and Republic of Ireland in the era of effective an-
tiretroviral therapy. Pediatr Infect Dis J 2006;25:420–426.
2. Wood E, Hogg RS, Yip B, et al. Effect of medication adherence
on survival of HIV-infected adults who start highly active
antiretroviral therapy when the CD4þ cell count is 0.200 to
0.35010(9) cells/L. Ann Intern Med 2003;139:810–816.
3. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci
A, Lyall H. Adherence to prescribed antiretroviral therapy in
human immunodeficiency virus-infected children in the
PENTA 5 trial. Pediatr Infect Dis J 2003;22:56–62.
4. Hogg RS, Yip B, Kully C, et al. Improved survival among
HIV-infected patients after initiation of triple-drug anti-
retroviral regimens. CMAJ 1999;160:659–665.
5. Needham DM, Hogg RS, Yip B, O’Shaughnessy M,
Schechter MT, Montaner JS. The impact of antiretroviral
therapy on AIDS survival observed in a province-wide drug
treatment programme. Int J STD AIDS 1998;9:370–372.
6. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of
HIV-infected orphaned and non-orphaned children on an-
tiretroviral therapy in western Kenya. J Acquir Immune
Defic Syndr 2006;43:418–425.
7. Bracher L, Valerius NH, Rosenfeldt V, et al. Long-term ef-
fectiveness of highly active antiretroviral therapy (HAART)
in perinatally HIV-infected children in Denmark. Scand J
Infect Dis 2007;39:799–804.
8. UNAIDS. 2006 Report on the global AIDS epidemic. The Joint
United Nations Programme on HIV/AIDS (UNAIDS); 2006.
9. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence
to highly active antiretroviral therapy predicts progression
to AIDS. AIDS 2001;15:1181–1183.
10. Boon-Yasidhi V, Kottapat U, Durier Y, et al. Diagnosis dis-
closure in HIV-infected Thai children. J Med Assoc Thai
2005;88(Suppl 8):S100–105.
11. Butler AM, Williams PL, Howland LC, Storm D, Hutton N,
Seage GR, 3rd. Impact of disclosure of HIV infection on
health-related quality of life among children and adolescents
with HIV infection. Pediatrics 2009;123:935–943.
12. Menon A, Glazebrook C, Campain N, Ngoma M. Mental
health and disclosure of HIV status in Zambian adolescents
with HIV infection: Implications for peer-support programs.
J Acquir Immune Defic Syndr 2007;46:349–354.
13. Oberdorfer P, Puthanakit T, Louthrenoo O, Charnsil C, Sir-
isanthana V, Sirisanthana T. Disclosure of HIV/AIDS diag-
nosis to HIV-infected children in Thailand. J Paediatr Child
Health 2006;42:283–288.
14. Marhefka SL, Tepper VJ, Brown JL, Farley JJ. Caregiver
psychosocial characteristics and children’s adherence to an-
tiretroviral therapy. AIDS Patient Care STDs 2006;20:
429–437.
15. Mellins C, Brackis-Cott E, Dolezal C, Richards A, Nicholas S,
Abrams E. Patterns of HIV status disclosure to perinatally
HIV-infected children and subsequent mental health out-
comes. Clin Child Psychol Psych 2002;7:101–114.
16. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role
of psychosocial and family factors in adherence to anti-
retroviral treatment in human immunodeficiency virus-
infected children. Pediatr Infect Dis J 2004;23:1035–1041.
17. Brackis-Cott E, Mellins CA, Abrams E, Reval T, Dolezal C.
Pediatric HIV medication adherence: The views of medical
providers from two primary care programs. J Pediatr Health
Care 2003;17:252–260.
18. Wiener L, Mellins CA, Marhefka S, Battles HB. Disclosure of
an HIV diagnosis to children: History, current research, and
future directions. J Dev Behav Pediatr 2007;28:155–166.
648 VREEMAN ET AL.
19. Gerson AC, Joyner M, Fosarelli P, et al. Disclosure of HIV
diagnosis to children: when, where, why, and how. J Pediatr
Health Care 2001;15:161–167.
20. Hammami N, Nostlinger C, Hoeree T, Lefevre P, Jonckheer
T, Kolsteren P. Integrating adherence to highly active anti-
retroviral therapy into children’s daily lives: A qualitative
study. Pediatrics 2004;114:e591–597.
21. Myer L, Moodley K, Hendricks F, Cotton M. Healthcare
providers’ perspectives on discussing HIV status with in-
fected children. J Trop Pediatr 2006;52:293–295.
22. Moodley K, Myer L, Michaels D, Cotton M. Paediatric HIV
disclosure in South Africa—Caregivers’ perspectives on discuss-
ing HIV with infected children. S Afr Med J 2006;96:201–204.
23. Vaz L, Corneli A, Dulyx J, et al. The process of HIV status
disclosure to HIV-positive youth in Kinshasa, Democratic
Republic of the Congo. AIDS Care 2008;20:842–852.
24. Bikaako-Kajura W, Luyirika E, Purcell DW, et al. Disclosure of
HIV status and adherence to daily drug regimens among HIV-
infected children in Uganda. AIDS Behav 2006;10:S85–93.
25. Nabukeera-Barungi N, Kalyesubula I, Kekitiinwa A,
Byakika-Tusiime J, Musoke P. Adherence to antiretroviral
therapy in children attending Mulago Hospital, Kampala.
Ann Trop Paediatr 2007;27:123–131.
26. Biadgilign S, Deribew A, Amberbir A, Deribe K. Adherence
to highly active antiretroviral therapy and its correlates
among HIV infected pediatric patients in Ethiopia. BMC
Pediatr 2008;8:53.
27. Vaz L, Eng E, Maman S, Tshikandu T, Behets F. Telling
children they have HIV: Lessons learned from findings of a
qualitative study in sub-Saharan Africa. AIDS Patient Care
STDs 2010;24:247–256.
28. Pequegnat W, Page B, Strauss A, et al. Qualitative inquiry:
An underutilized strategy in AIDS research. In: Pequegnat
W, Stover E, eds. How to Write a Successful Research Grant
Application. New York: Plenum Press, 1995:97–113.
29. Miller WL, Crabtree BF. Clinical research: A multimethod
typology and qualitative roadmap. In: Crabtree BF, Miller
WL, eds. Doing Qualitative Research. 2nd edition. Thousand
Oaks, CA: Sage Publications, 1999:6–32.
30. Sankar A, Golin C, Simoni JM, Luborsky M, Pearson C. How
qualitative methods contribute to understanding combina-
tion antiretroviral therapy adherence. J Acquir Immune Defic
Syndr 2006;43(Suppl 1):S54–68.
31. Strauss A, Corbin J. Basics of Qualitative Research: Groun-
ded Theory Procedures and Techniques. Newbury Park, CA:
SAGE Publications, 1990.
32. Glaser B, Strauss A. The Discovery of Grounded Theory:
Strategies for Qualitative Research. New York: Aldine
Publishing Company, 1967.
33. Quigley F. Walking Together, Walking Far: How a U.S. and
African Medical School Partnership is Winning the Fight
Against HIV/AIDS. Bloomington, Indiana: Indiana Uni-
versity Press, 2009.
34. Einterz RM, Kimaiyo S, Mengech HN, et al. Responding to
the HIV pandemic: The power of an academic medical
partnership. Acad Med 2007;82:812–818.
35. 2007 Kenya AIDS Indicatory Survey. Nairobi, Kenya: Kenya
Ministry of Health, 2008.
36. Vreeman RC, Nyandiko WM, Ayaya SO, Walumbe EG,
Marrero DG, Inui TS. Factors sustaining pediatric adherence
to antiretroviral therapy in western Kenya. Qual Health Res
2009;19:1716–1729.
37. Kreuger RA. Focus Groups: A Practical Guide for Applied
Research, 2nd ed. Thousand Oaks, CA: Sage Publications, 1994.
38. Morgan DL, Kreuger RA. The Focus Group Kit. Thousand
Oaks, CA: Sage Publications, 1998.
39. Landis JR, Koch GG. The measurement of observer agree-
ment for categorical data. Biometrics 1977;33:159–174.
40. Giacomini MK, Cook DJ. Users’ guides to the medical lit-
erature: XXIII. Qualitative research in health care A. Are the
results of the study valid? Evidence-Based Medicine Work-
ing Group. JAMA 2000;284:357–362.
41. Giacomini MK, Cook DJ. Users’ guides to the medical lit-
erature: XXIII. Qualitative research in health care B. What
are the results and how do they help me care for my
patients? Evidence-Based Medicine Working Group. JAMA
2000;284:478–482.
42. De Baets AJ, Sifovo S, Parsons R, Pazvakavambwa IE. HIV
disclosure and discussions about grief with Shona children: A
comparison between health care workers and community
members in Eastern Zimbabwe. Soc Sci Med 2008;66:479–491.
43. MacDonald K, Shankardass K, Kimani G, et al. An explor-
atory study of the knowledge, attitudes and beliefs (KAB) of
adolescents in Nairobi with respect to the disclosure of HIV
status." Int Conf AIDS 2004;15:11–16.
44. Abadia-Barrero CE, Larusso MD. The disclosure model
versus a developmental illness experience model for chil-
dren and adolescents living with HIV/AIDS in Sao Paulo,
Brazil. AIDS Patient Care STDs 2006;20:36–43.
45. Moodley K, Myer L. Paediatric HIV disclosure in South
Africa—Caregivers’ perspectives on discussing HIV with
infected children. S Afr Med J 2006;96:201–204.
46. Weiner L, Mellins C, Marhefka S, Battles H. Disclosure of an
HIV diagnosis to children: History, current research, and
future directions. J Dev Behav Pediatr 2007;28:155–166.
47. Menon A, Glazebrook C, Campain N, Ngoma M. Mental
health and disclosure of HIV status in Zambian adolescents
with HIV infection: Implications for peer-support programs.
J Acquir Immune Defic Syndr 2007;26:349–354.
48. Butler A, Williams P, Howland L, Storm D, Hutton N, Seage
G. Impact of disclosure of HIV infection on health-related
quality of life among children and adolescents with HIV
infection. Pediatrics 2009;123:935–943.
49. Vreeman RC, Nyandiko WM, Meslin EM. Pediatric assent
for a study of antiretroviral therapy dosing for children in
Western Kenya: A case study in international research col-
laboration. J Empir Res Hum Res Ethics 2009;4:3–16.
50. Vreeman RC, Wiehe SE, Ayaya SO, Musick BS, Nyandiko
WM. Association of antiretroviral and clinic adherence with
orphan status among HIV-infected children in western
Kenya. J Acquir Immune Defic Syndr 2008;49:163–170.
51. Vreeman RC, Nyandiko WM, Sang E, Musick BS, Braitstein
P, Wiehe SE. Impact of the Kenya post-election crisis on
clinic attendance and medication adherence for HIV-infected
children in western Kenya. Confl Health 2009;3:5.
52. Disclosure of illness status to children and adolescents with
HIV infection. American Academy of Pediatrics Committee
on Pediatrics AIDS. Pediatrics 1999;103:164–166.
Address correspondence to:
Rachel C. Vreeman, M.D., M.S.
Children’s Health Services Research
Health Information and Translational Sciences Building
Suite #1020
410 West 10th Street
Indianapolis, IN 46202
E-mail: rvreeman@iupui.edu
PERCEIVED IMPACT OF DISCLOSURE OF PEDIATRIC HIV STATUS 649

